There are 2867 resources available
127P - Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy
Presenter: Younes Belkouchi
Session: Poster session 01
128P - Histopathology (HP) biomarkers confirm leukocyte interleukin injection (LI) treatment (Tx) outcome in naïve locally advanced primary head & neck squamous cell carcinoma (SCCHN) the IT-MATTERS study
Presenter: Jozsef Timar
Session: Poster session 01
130P - Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)
Presenter: Aesha Gandhi
Session: Poster session 01
131P - Frequency of germline testing after tumor sequencing by cancer type
Presenter: Hannah Karpel
Session: Poster session 01
132TiP - Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)
Presenter: Stefan Kasper
Session: Poster session 01
143P - Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+ breast cancer. A systematic review and network meta-analysis (NMA)
Presenter: Guillermo Villacampa Javierre
Session: Poster session 01
144P - Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study
Presenter: Aditya Bardia
Session: Poster session 01
145P - Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: A TRAIN-2 sub study
Presenter: Marte Liefaard
Session: Poster session 01